NEUROLOGY 2004;63:828-831
© 2004 American Academy of Neurology
Plasma levels of amyloid ß-protein 42 are increased in women with mild cognitive impairment
A. Assini, MD*,
S. Cammarata, MD*,
A. Vitali, PhD,
M. Colucci, MD,
L. Giliberto, MD,
R. Borghi, PhD,
M. L. Inglese, BSc,
S. Volpe, BSc,
S. Ratto, MD,
F. Dagna-Bricarelli, MD,
C. Baldo, PhD,
A. Argusti, PhD,
P. Odetti, MD,
A. Piccini, PhD and
M. Tabaton, MD
From the Departments of Neurosciences (Drs. Assini, Vitali, Colucci, Giliberto, Borghi, Piccini, and Tabaton, and M.L. Inglese and S. Volpe) and Internal Medicine (Dr. Odetti), University of Genoa; and the Departments of Neurology (Drs. Cammarata and Ratto) and Human Genetics (Drs. Dagna-Bricarelli, Baldo, and Argusti), Galliera Hospital, Genoa, Italy.
Address correspondence and reprint requests to Dr. Massimo Tabaton, Department of Neurosciences, University of Genoa, Via De Toni 5, 16132 Genoa, Italy; e-mail: mtabaton{at}neurologia.unige.it
Background: Accumulation in the brain of small aggregates of amyloid ß-protein 42 (Aß42) is the major pathogenic event of Alzheimer disease (AD). In familial early-onset AD this event is likely the result of Aß42 overproduction; in the most common sporadic late-onset form of the disease the mechanisms of Aß42 accumulation are unknown.
Methods: To address this issue the authors analyzed plasma levels of Aß42 in 88 elderly patients with amnestic mild cognitive impairment (MCI), chosen as paradigm of preclinical sporadic AD.
Results: The authors found a significant increase of Aß42 plasma levels in women with MCI, in comparison to the affected men and 72 cognitively normal age-matched subjects. The levels were independent of variables in education, apolipoprotein E genotype, cholesterol, and creatinine plasma concentrations, as well as hemoglobin content.
Conclusions: The elevation of Aß42 plasma levels in women with MCI may represent a biologic explanation for the sex-dependent increased incidence of late-onset AD in women identified by epidemiologic studies.
Received January 7, 2004.
Accepted in final form April 28, 2004.
*These authors contributed equally to the study.
Related Article
-
September 14 Highlights
Neurology 2004 63: 766-767.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
W. Xia, T. Yang, G. Shankar, I. M. Smith, Y. Shen, D. M. Walsh, and D. J. Selkoe
A Specific Enzyme-Linked Immunosorbent Assay for Measuring {beta}-Amyloid Protein Oligomers in Human Plasma and Brain Tissue of Patients With Alzheimer Disease
Arch Neurol,
February 1, 2009;
66(2):
190 - 199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Britschgi and T. Wyss-Coray
Blood Protein Signature for the Early Diagnosis of Alzheimer Disease
Arch Neurol,
February 1, 2009;
66(2):
161 - 165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Schupf, M. X. Tang, H. Fukuyama, J. Manly, H. Andrews, P. Mehta, J. Ravetch, and R. Mayeux
Peripheral A{beta} subspecies as risk biomarkers of Alzheimer's disease
PNAS,
September 16, 2008;
105(37):
14052 - 14057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Locascio, H. Fukumoto, L. Yap, T. Bottiglieri, J. H. Growdon, B. T. Hyman, and M. C. Irizarry
Plasma Amyloid {beta}-Protein and C-reactive Protein in Relation to the Rate of Progression of Alzheimer Disease
Arch Neurol,
June 1, 2008;
65(6):
776 - 785.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Sun, D. C. Steffens, R. Au, M. Folstein, P. Summergrad, J. Yee, I. Rosenberg, D. M. Mwamburi, and W. Q. Qiu
Amyloid-Associated Depression: A Prodromal Depression of Alzheimer Disease?
Arch Gen Psychiatry,
May 1, 2008;
65(5):
542 - 550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. M. Brust
A 74-Year-Old Man With Memory Loss and Neuropathy Who Enjoys Alcoholic Beverages
JAMA,
March 5, 2008;
299(9):
1046 - 1054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sundelof, V. Giedraitis, M. C. Irizarry, J. Sundstrom, E. Ingelsson, E. Ronnemaa, J. Arnlov, M. D. Gunnarsson, B. T. Hyman, H. Basun, et al.
Plasma {beta} Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men: A Prospective, Population-Based Cohort Study
Arch Neurol,
February 1, 2008;
65(2):
256 - 263.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-Q. Zhao, F. G. De Felice, S. Fernandez, H. Chen, M. P. Lambert, M. J. Quon, G. A. Krafft, and W. L. Klein
Amyloid beta oligomers induce impairment of neuronal insulin receptors
FASEB J,
January 1, 2008;
22(1):
246 - 260.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Miyashita, H. Arai, T. Asada, M. Imagawa, E. Matsubara, M. Shoji, S. Higuchi, K. Urakami, A. Kakita, H. Takahashi, et al.
Genetic association of CTNNA3 with late-onset Alzheimer's disease in females
Hum. Mol. Genet.,
December 1, 2007;
16(23):
2854 - 2869.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Schupf, B. Patel, D. Pang, W. B. Zigman, W. Silverman, P. D. Mehta, and R. Mayeux
Elevated Plasma beta-Amyloid Peptide Abeta42 Levels, Incident Dementia, and Mortality in Down Syndrome
Arch Neurol,
July 1, 2007;
64(7):
1007 - 1013.
[Abstract]
[Full Text]
[PDF]
|
|
|
Correspondence:
Read all Correspondence
- Plasma levels of amyloid ß-protein 42 are increased in women with mild cognitive impairment
- Kurt A. Jellinger, et al.
- Neurology Online, 15 Dec 2004
[Full text]
|
